SingleNot ApprovedMixedVery Low confidenceSourced

CJC-1295 no DAC

A short-acting GHRH analogue name that does not map to the long-acting DAC-linked CJC-1295 used in the best-known human trials.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Community-reported schedule

Community-reported · not a validated schedule

Community dose schedule

A single community-provenance subcutaneous line from forum reports - no-DAC CJC-1295 clustering near 100-200 mcg daily, paired with ipamorelin and cycled. Community reports only, not a validated or trial-verified schedule.

Evidence source

Reported maximum quantity

Community daily (forum)

Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.

Reported quantities by phase

Select a point for its calculation examples

Community daily (SubQ)
200 mcg
Reports cluster near 100-200 mcg (up to ~300 mcg inside a blend), subcutaneously before bed or fasted pre-workout, commonly cycled 5 days on and 2 off; near-universally paired with ipamorelin.

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected 200 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator

Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface — One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.

BAC water selected

3 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

U-100 draw12 U

20-30 U reference band

1 mL BAC

4 units

resulting U-100 draw

Concentration: 5 mg/mL
BAC added: 1 mL

2 mL BAC

8 units

resulting U-100 draw

Concentration: 2.5 mg/mL
BAC added: 2 mL

3 mL BAC

12 units

resulting U-100 draw

Concentration: 1.667 mg/mL
BAC added: 3 mL

Shown in the diagram. Closest of these examples to 25 units.

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily

Third-party educational no-DAC schedule

100 mcg daily in weeks 1-2, 150 mcg in weeks 3-4, 200 mcg in weeks 5-6 and 250-300 mcg in weeks 7-12

No matched human no-DAC dose-finding trial validates this schedule. The published CJC-1295 study used the pharmacologically different long-acting DAC-linked molecule.

View source

Evidence Gap

Healthy adults in a long-acting CJC-1295 trial

The human study evaluated DAC-linked CJC-1295, not the no-DAC compound named on this page

This is an evidence-boundary card rather than a transferable dose. Its amounts and intervals must not be imported into no-DAC products.

View source

Community GuideSubcutaneous in reportsOnce or twice daily in the main cluster

online research community no-DAC plus ipamorelin reports

Reports cluster around 100 mcg no-DAC CJC-1295 plus 100-200 mcg ipamorelin once or twice daily, sometimes five days on and two days off

The archive admits the cycling rationale lacks evidence and records wider dosing. Its opening spotlight is explicitly described later as an erroneous AI placeholder; raw/peptide-education/pe-cjc-1295.md:8-26, 114-154 and 1133-1140.

View source

Community GuideSubcutaneous in reportsDaily; commonly 5 days on and 2 off

authenticated research-forum (Peppys) no-DAC CJC-1295 reports

Subcutaneous quantities cluster around 100-200 mcg of no-DAC CJC-1295, most often paired one-to-one with ipamorelin at 200/200 or 300/300 mcg, dosed before bed or fasted pre-workout and commonly cycled five days on and two off or in eight-to-twelve week blocks; some split 150/150 twice daily for the short half-life and titrate against IGF-1 testing

Forum provenance from an authenticated archive with usernames omitted. The archive keeps no-DAC CJC-1295 / Mod-GRF 1-29 separate from the long-acting DAC-linked molecule, notes the cycling rationale is convention rather than evidenced, and records conflicting quantities. These are community provenance, not controlled human dose finding.

View source

Evidence summary

A short-acting GHRH analogue name that does not map to the long-acting DAC-linked CJC-1295 used in the best-known human trials.

Protocol basis

The protocol basis is a formulation mismatch. The human study proves that DAC-linked CJC-1295 affects GH and IGF-1, but it cannot validate a no-DAC schedule.

Community provenance (Peppys)

An authenticated research-forum archive records subcutaneous no-DAC CJC-1295 quantities clustering around 100-200 mcg, most often paired one-to-one with ipamorelin and dosed before bed or fasted before training, with five-days-on/two-off and multi-week block cycling both described. The archive treats no-DAC CJC-1295 / Mod-GRF 1-29 as separate from the long-acting DAC-linked molecule and admits the cycling rationale is convention rather than evidence. Reported quantities conflict, usernames are omitted, and figures are logged as community provenance without endorsement. The planner above reproduces the arithmetic of these reported quantities; it does not validate them.

What remains uncertain

The identity behind retail no-DAC naming, human pharmacokinetics, validated intervals and clinical outcomes remain uncertain.

Warnings and contraindications

Published CJC-1295 human studies used a long-acting albumin-binding DAC formulation.

Long-acting study quantities and intervals cannot be applied to no-DAC products.

Growth-hormone and IGF-1 manipulation requires specialist endocrine context.

The online research community archive opening post conflates no-DAC CJC-1295 with growth-hormone fragment 176-191; those quantities are not a clean CJC protocol.

Organised research bench with labelled storage tray, vial rack, notebook and thermometer — A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.

General references: CDC injection safety, NHS medicine storage and DailyMed BAC water labelling.